AI assistant
Anteris Technologies Global Corp. — Board/Management Information 2018
Dec 11, 2018
33869_rns_2018-12-11_acd0e7ec-2a3b-448b-b124-8bf3a0226af8.pdf
Board/Management Information
Open in viewerOpens in your device viewer
12 December 2018
==> picture [451 x 24] intentionally omitted <==
ASX ANNOUNCEMENT
BOARD OF DIRECTORS APPOINTMENTS
Medical technologies firm Admedus Ltd. (ASX: AHZ, “Admedus” or “the Company”) has appointed Lishan Zhang and Dr Yanheng Wu as non-executive directors, representing its major investor Star Bright Holding Ltd.
Ms Zhang is a highly successful businesswoman and entrepreneur with a significant network in China that will greatly benefit Admedus. Ms Zhang is the Chair of Constellation International Group Holdings Ltd., a Hong Kong-based company with multiple interests in the development of new biotechnology assets including vaccines, nanotechnology, biomedical materials and minimally invasive tumour treatments. She is also Vice-Chair at Guangzhou Hearty-Care Biotechnology Ltd. and has leadership experience in the areas of strategy, development and financial oversight.
Dr Wu is the President and Managing Director of Constellation International Group Holdings Ltd. and has a PhD in tumour immunotherapy and nanocarrier technology from The University of Queensland. In 2016, he established Guangzhou Hearty-Care Biotechnology Ltd., a medical technology company that is now owned by Constellation International Group Holdings Ltd.
“I am very excited to welcome both Ms Zhang and Dr Wu to our Board of Directors. As a major investor, Star Bright’s interest is aligned with our shareholders, and they are committed to furthering the commercial and development success of Admedus,” said Admedus CEO Wayne Paterson.
“China is a very important market within our global growth strategy. Both Ms Zhang and Dr Wu bring commercial and scientific experience and networks, which will be of great value.”
Constellation International Group Holdings Ltd. is strengthening its capabilities in the research and development of medical technology and commercialising innovative products. The Company plans to build a world-class life science industry complex in Shenzhen. It intends to form a joint venture with Admedus to help resource commercial operations in China and fund clinical development programs.
ENDS
Admedus Limited
Registered Office:
Level 9, 301 Coronation Drive, Milton, Queensland 4064
T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299 E: [email protected] W: admedus.com
==> picture [72 x 72] intentionally omitted <==
Customer Service:
Brisbane • Minneapolis • Geneva • Singapore
ABN 35 088 221 078
==> picture [451 x 24] intentionally omitted <==
About Admedus Limited
Admedus (ASX: AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next-generation technologies with world-class partners, acquiring strategic assets to grow product and service offerings, and expanding revenues from our existing medical sales and distribution business. The Company has assets from research & development through clinical development and sales, marketing and distribution.
Website: www.admedus.com
Facebook: www.facebook.com/Admedus
Twitter: @Admedus
For more information, please contact:
About Guangzhou Hearty-Care Biotechnology Limited
Guangzhou Hearty-Care Biotechnology Ltd. is an innovative medical enterprise dedicated to the research and development the best biological immunotherapy technologies and resolving the most challenging health problems. Hearty-Care developed a comprehensive, innovative system in many areas, including biological immunotherapy, stem cell research, nanotechnology and precise healthcare. Guangzhou Hearty-Care Biotechnology Ltd. is a subsidiary of Constellation International Group Holdings Ltd.
About Constellation International Group Holdings Ltd.
Constellation International Group Holdings Ltd. is a medical technology holding company. The Company focuses on several areas, including vaccines technology, biological immunotherapy, nanotechnology, biomedical materials and minimally invasive tumour treatments. The group comprises of four companies, including Shenzhen International Translational Research Institute, Constellation Therapeutics Ltd., Constellation Immunotherapy Ltd. and Admedus Ltd.
==> picture [21 x 19] intentionally omitted <==